Discussion on the AQUARiUS and EXCAAPE studies- Thomas Keane
Thomas Keane, MD reviews three state of the art presentations from the 2017 European Society for Medical Oncology (ESMO) meeting.
Dr. Keane highlights the AQUARiUS study presented by Antoine Thiery-Vuillemin who overviewed the initial results from this patient reported outcomes (PROs) study among men receiving either abiraterone + prednisone or enzalutamide. The second study reviewed is the EXCAAPE study, a phase II clinical trial of Radium-223 activity in patients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status.
Dr. Keane concludes his discussion with a review of the a presentation by Nicholas D. James on adding abiraterone acetate for patients with high-risk prostate cancer starting long-term ADT: Outcomes in non-metastatic patients from STAMPEDE.
Additional Content on Prostate Cancer coverage from ESMO 2017
Watch: Commentary by Thomas Keane: Cancer Highlights from ESMO 2017
ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide
ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE)
ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE
Thomas E. Keane, MBBCh, FRCSI, FACS